Two biotechs are again mounting IPO efforts after market volatility scuttled their first attempts, as Molecular Partners and Xenon Pharmaceuticals pitch downsized offerings in hopes of finally making onto the public markets.
More than three years after inking a $750 million pact to develop Intra-Cellular's PDE1 inhibitors for cognitive impairment caused by schizophrenia, Takeda is out.
Bristol-Myers Squibb has grabbed an option on an early-stage program for idiopathic pulmonary fibrosis this morning, forging a deal to potentially buy out Denmark's Galecto Biotech for up to $444 million--if the drug pans out in the clinic.
After putting up evidence to show that the liver toxicity triggered by its lead drug can be reversed, the FDA has lifted the full hold placed on its lead--and only--cancer drug. And investors responded enthusiastically to the biotech's return to the clinic, boosting shares by 35% in premarket trading.
LabCorp is diversifying. The big diagnostics player has swooped in to buy the contract research organization Covance for $6.1 billion in cash and stock, confident that a combination of its expertise with Covance's approach to contract drug development will make for a successful merger.
Nymox Pharmaceutical is headed for a bruising opening this morning after putting out word on Sunday that both their late-stage studies of their lead drug flopped as a treatment for enlarged prostate. Partnered with Italy's Recordati, the biotech put out a brief statement blaming the failure on an unexpectedly high placebo response.
Novartis has leased a sizable outpost in the Philadelphia suburbs, according to a local report, settling into the area as it works with University of Pennsylvania researchers on a promising new approach to treating cancer.
Impax Laboratories is slashing its R&D payroll and moving away from early-stage research, a move designed to save cash in the midst of a costly transition.
Novo Nordisk has broken ground on a new R&D shop in its native Denmark, plotting a $130 million project that will expand its wide footprint in diabetes research.
In an uncommon move, the FDA has publicly weighed in on an in-development drug, clarifying the status of Sarepta Therapeutics' closely watched Duchenne muscular dystrophy treatment eteplirsen in light of an earlier setback that tanked the biotech's shares.
The band behind FerroKin BioSciences, a pioneer of the virtual biotech model, has gotten back together to take a stab at epigenetics, raising $26.5 million from some A-list investors to develop new treatments for orphan diseases.
A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.
In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of antibiotic R&D with the goal of making antibiotic R&D economically attractive again. And more.
For the now-former chief of Sanofi, Chris Viehbacher, there's plenty of money for a cushion, but it won't be nearly as plump as the packages granted to his counterparts in the U.S.
Cortendo is coming to America. Founded in Sweden, the little biotech has a new CEO who's building the executive team in the Philadelphia area. And he's dropping plans for a listing on the Oslo exchange in favor of a U.S. IPO after raising $11 million in bridge financing.
AstraZeneca won an FDA nod for a one-pill combination of its latest diabetes drug and the long-generic metformin, making it the second to market among a cadre of drugmakers developing similar cocktails.
Bristol-Myers Squibb's closely watched checkpoint inhibitor nivolumab managed to wow analysts this morning with impressive survival results in a Phase II study of patients with advanced squamous cell non-small cell lung cancer. Of all the patients in the drug arm, 41% were alive at the one-year mark, while investigators tracked an overall response rate of 15%.
Novo Nordisk is sounding a more cautious tone on Tresiba, its once-rejected new insulin. After hinting at an accelerated trip back to the FDA for the long-acting diabetes treatment, the Danish drugmaker now says it could be another few years before the injection is ready for another shot at approval.
The Cleveland Clinic's annual list of the most promising medical innovations reads a bit like a biopharma yearbook, name-checking a slew of potential blockbuster treatments and affirming the potential of some of the biggest targets in drug development.